Physician profile
Daniel Maestas
NPI 1407823511
$3,040.26
in general payments reported to CMS, 2019-2025
27 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $858 · 2020: $197 · 2021: $13.84 · 2022: $136 · 2023: $79.04 · 2024: $1,404 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,836.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.91 | 2022-2025 | |
| Pfizer INC. | $320.66 | 2019-2025 | |
| Novo Nordisk INC | $260.84 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $237.71 | 2019-2024 | Airsupra, Farxiga |
| Lilly USA, LLC | $231.66 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $202.63 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $182.46 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.96 | 2019-2025 | Trintellix |
| Amgen INC. | $123.85 | 2020-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $99.30 | 2019-2020 | |
| Biogen, INC. | $93.51 | 2022 | |
| Exact Sciences Corporation | $78.13 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.09 | 2019 | |
| Janssen Pharmaceuticals, INC | $69.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $48.13 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $46.91 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.63 | 2019-2020 | |
| Celgene Corporation | $40.79 | 2019 | |
| Sumitomo Pharma America, INC. | $40.28 | 2024 | Gemtesa |
| Abbott Laboratories | $38.84 | 2024 | Freestyle Libre 3 |
| Shire North American Group INC | $37.00 | 2019 | |
| Merck Sharp & Dohme LLC | $36.75 | 2019-2020 | |
| Axsome Therapeutics, INC. | $35.43 | 2024-2025 | Auvelity |
| Viiv Healthcare Company | $24.09 | 2024 | Apretude |
| Amarin Pharma, INC. | $22.39 | 2019-2020 | |
| Sanofi Pasteur INC. | $15.53 | 2019 | |
| Alkermes, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Maestas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.